Collagen-derived peptides to target inflammation in myocardial infarction
胶原蛋白衍生肽可靶向心肌梗塞炎症
基本信息
- 批准号:10366741
- 负责人:
- 金额:$ 37.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-15 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:ActinsBiologicalCardiacCellsCicatrixClinical TrialsCollagenCongestive Heart FailureDataDepositionDiagnosisDrug or chemical Tissue DistributionEquilibriumEventExtracellular MatrixExtracellular Matrix DegradationFamilyFiberFibroblastsFibrosisFoundationsGelatinase BGenerationsHeart failureHumanIn VitroInfiltrationInflammationInflammatoryInflammatory ResponseInhibition of Matrix Metalloproteinases PathwayIntegrin alpha4IntegrinsKnowledgeLeadLeft Ventricular RemodelingLeft ventricular structureMatrix Metalloproteinase InhibitorMatrix MetalloproteinasesMediatingMolecularMusMyocardialMyocardial InfarctionMyocardial dysfunctionParacrine CommunicationPathway interactionsPatientsPeptide HydrolasesPeptide ReceptorPeptidesPharmacologyPhasePhenotypePhysiologyPlasmaProcessProteolysisProteomicsReportingResolutionRoleSignal PathwaySignal TransductionSpecificitySpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTestingTherapeuticTissuesTransgenic Animalscellular targetingheart functionimprovedin vivoinhibitorinnovationmacrophagemass spectrometric imagingmigrationmimeticsmonocytemortalitymultiple reaction monitoringneutrophilnovelnovel therapeuticsparacrinepolymerizationpredict clinical outcomepreferencepressureprognostic indicatorreceptorrepairedresponserho GTP-Binding Proteinssynthetic peptide
项目摘要
PROJECT SUMMARY
Myocardial infarction (MI) leads to the generation of a scar that is mostly constituted by cardiac extracellular
matrix (ECM). The balance between degradation and deposition of ECM is a strong predictor of clinical
outcomes. ECM degradation occurs by matrix metalloproteinases (MMPs); and ECM deposition occurs by
cardiac fibroblasts. Both ECM degradation and deposition promote adverse remodeling and progression to heart
failure. Within the MMP family, MMP-9 has been reported as a prognostic indicator of cardiac dysfunction in
myocardial infarction (MI) patients; as MMP-9 levels directly associate with patient mortality. Thus, the advantage
of inhibiting MMP-9 after MI has been long recognized. However, clinical trials using global MMP-9 inhibition
have mostly failed both due to lack of MMP inhibitor specificity and importance of MMP-9 in several essential
processes.
We recently identified an ECM-derived peptide (p1159) that acts as a competitive and specific MMP-9 substrate.
Herein, we propose use of p1159 to modulate MMP-9 cleavage of native substrates post-MI. This approach does
not inhibit MMP-9 activity, allowing it to participate in essential processes; instead, it modulates MMP-9
proteolytic capacity to reduce cleavage of endogenous substrates that promote inflammation and inhibit repair.
The synthetic peptide p1159 is a mimetic of the naturally formed fragment C-1158/59 generated by MMP-9
cleavage of collagen post-MI. In humans, plasma levels of endogenous C-1158/59 post-MI correlate with lower
left ventricle filling pressure, indicating a therapeutic potential of C-1158/59. Indeed, mice treated with exogenous
p1159 post-MI display less LV dilation, reduced inflammation and fibrosis, and improved cardiac function. In
vitro, we identified integrin α4 (Itga4) as a peptide receptor. While we know that exogenous delivery is beneficial,
how p1159 regulates post-MI inflammation and ECM deposition has not been mechanistically dissected.
Accordingly, the central hypothesis of this proposal is that p1159 blunts adverse remodeling after MI by serving
as a competitive substrate to reduce MMP-9 proteolysis of substrates necessary for promotion of inflammation
and ECM deposition. To elucidate the mode-of-action and signaling pathways mediated by p1159 in the post-MI
setting, we will use cell-specific Itga4 transgenic animals to identify the mechanisms whereby p1159 tempers
the post-MI inflammatory response, modulates cardiac fibroblast signaling to reduce ECM secretion; and
promotes macrophage-fibroblast crosstalk.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lisandra E de Castro Bras其他文献
Lisandra E de Castro Bras的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lisandra E de Castro Bras', 18)}}的其他基金
Collagen-derived peptides to target inflammation in myocardial infarction
胶原蛋白衍生肽可靶向心肌梗塞炎症
- 批准号:
10540744 - 财政年份:2021
- 资助金额:
$ 37.2万 - 项目类别:
相似海外基金
CPS: Medium: An AI-enabled Cyber-Physical-Biological System for Cardiac Organoid Maturation
CPS:中:用于心脏类器官成熟的人工智能网络物理生物系统
- 批准号:
2038603 - 财政年份:2020
- 资助金额:
$ 37.2万 - 项目类别:
Standard Grant
Post-VAD implant cardiac remodeling: molecular biological analysis focusing on Fhod3, cytoskeleton-related protein
VAD 植入后心脏重塑:关注细胞骨架相关蛋白 Fhod3 的分子生物学分析
- 批准号:
19K18187 - 财政年份:2019
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Synthetic Biological Engineering of Self-Assembling Micro-Hearts for Cardiac Drug Testing
用于心脏药物检测的自组装微型心脏的合成生物工程
- 批准号:
EP/P016898/1 - 财政年份:2017
- 资助金额:
$ 37.2万 - 项目类别:
Fellowship
Modulation of cardiac cell signaling with synthetic antibodies, and their characterization as potential therapeutics and probes for basic biological research
用合成抗体调节心脏细胞信号传导,及其作为基础生物学研究潜在疗法和探针的表征
- 批准号:
366643 - 财政年份:2016
- 资助金额:
$ 37.2万 - 项目类别:
Operating Grants
Nonlinear and bifurcation analysis of mathematical models of cardiac myocytes for the creation of biological pacemaker
用于创建生物起搏器的心肌细胞数学模型的非线性和分岔分析
- 批准号:
15K00337 - 财政年份:2015
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Beating cardiomyocyte induction from iPS cells on acellular cardiac tissues with native biological niche
在具有天然生物生态位的无细胞心脏组织上通过 iPS 细胞诱导跳动心肌细胞
- 批准号:
26560251 - 财政年份:2014
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Analyses of biological significance of STAT3/Pim-1 signaling in cardiac stem cells
心脏干细胞中STAT3/Pim-1信号传导的生物学意义分析
- 批准号:
25860061 - 财政年份:2013
- 资助金额:
$ 37.2万 - 项目类别:
Grant-in-Aid for Young Scientists (B)